Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group

Abstract It is increasingly common in oncology practice to perform tumour sequencing using large cancer panels. For pathogenic sequence variants in cancer susceptibility genes identified on tumour-only sequencing, it is often unclear whether they are of somatic or constitutional (germline) origin. There is wide-spread disparity regarding both the extent to which systematic ‘germline-focussed analysis’ is carried out upon tumour sequencing data and for which variants follow-up analysis of a germline sample is carried out. Here we present analyses of paired sequencing data from 17 152 cancer samples, in which 1494 pathogenic sequence variants were identified across 65 cancer susceptibility genes. From these analyses, the European Society of Medical Oncology Precision Medicine Working Group Germline Subgroup has generated (i) recommendations regarding germline-focussed analyses of tumour-only sequencing data, (ii) indications for germline follow-up testing and (iii) guidance on patient information-giving and consent.

[1]  R. Houlston,et al.  Cancer genetics, precision prevention and a call to action , 2018, Nature Genetics.

[2]  S. Ellard,et al.  p.Val804Met, the Most Frequent Pathogenic Mutation in RET, Confers a Very Low Lifetime Risk of Medullary Thyroid Cancer , 2018, The Journal of clinical endocrinology and metabolism.

[3]  P. Kantoff,et al.  Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing , 2017, JAMA.

[4]  Donavan T. Cheng,et al.  Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing , 2017, BMC Medical Genomics.

[5]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[6]  L. Macconaill,et al.  Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer. , 2017, Archives of pathology & laboratory medicine.

[7]  B. Taylor,et al.  Implementing Genome-Driven Oncology , 2017, Cell.

[8]  W. Chung,et al.  Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.

[9]  L. Strotman,et al.  The Future of Precision Medicine in Oncology. , 2016, Clinics in laboratory medicine.

[10]  Sheri D Schully,et al.  A standardized, evidence-based protocol to assess clinical actionability of genetic disorders associated with genomic variation , 2016, Genetics in Medicine.

[11]  Lara E Sucheston-Campbell,et al.  Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. , 2015, Journal of the National Cancer Institute.

[12]  J. Berg,et al.  Incidental Findings with Genomic Testing: Implications for Genetic Counseling Practice , 2015, Current Genetic Medicine Reports.

[13]  J. Berg,et al.  A semiquantitative metric for evaluating clinical actionability of incidental or secondary findings from genome-scale sequencing , 2015, Genetics in Medicine.

[14]  Nazneen Rahman,et al.  Gene-panel sequencing and the prediction of breast-cancer risk. , 2015, The New England journal of medicine.

[15]  Funda Meric-Bernstam,et al.  Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[17]  A. StAteMent.  ACMG policy statement: updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing , 2014, Genetics in Medicine.

[18]  Nazneen Rahman,et al.  Breast-cancer risk in families with mutations in PALB2. , 2014, The New England journal of medicine.

[19]  Nazneen Rahman,et al.  Realizing the promise of cancer predisposition genes , 2014, Nature.

[20]  Deanna M. Church,et al.  ClinVar: public archive of relationships among sequence variation and human phenotype , 2013, Nucleic Acids Res..

[21]  Alex M. Fichtenholtz,et al.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.

[22]  Marc S. Williams,et al.  ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.

[23]  S. Seal,et al.  Germline RAD51C mutations confer susceptibility to ovarian cancer , 2012, Nature Genetics.

[24]  Deborah Hughes,et al.  Germline mutations in RAD51D confer susceptibility to ovarian cancer , 2011, Nature Genetics.

[25]  J. Schleutker,et al.  RAD51C is a susceptibility gene for ovarian cancer. , 2011, Human molecular genetics.

[26]  David N Louis,et al.  Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine , 2010, EMBO molecular medicine.

[27]  Bartha Maria Knoppers,et al.  Population genetic testing for cancer susceptibility: founder mutations to genomes , 2016, Nature Reviews Clinical Oncology.